$1.14/ day, billed weekly
Cancel anytime

(Ad-Free, Unlimited access)

NO CREDIT CARD REQUIRED

GMDAQ

Gamida Cell Ltd (GMDAQ)

$0.02

Last Close (24-hour delay)

PASS

BUY Advisory
SELL Advisory (Profit)
SELL Advisory (Loss)

Profit
Loss
Pass (Skip investing)

Time period over

ALL
YEAR
MONTH
WEEK

Upturn Advisory Summary

05/20/2024: GMDAQ (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $

Analysts Price Target For last 52 week

$Target price

Low$

Current$0.02

high$

Trends

0	Strong Buy
1	Buy
1	Hold
0	Sell
0	Strong Sell

Analysis of Past Performance

Type Stock

Historic Profit -28.66%

Avg. Invested days 29

Today’s Advisory PASS

Upturn Star Rating

Upturn Advisory Performance

3.0

Stock Returns Performance

1.0

Profits based on simulation

Last Close 05/20/2024

Key Highlights

Company Size ETF	Market Capitalization 0 USD	Price to earnings Ratio -	1Y Target Price -
Price to earnings Ratio -	1Y Target Price -
Volume (30-day avg) -	Beta -	52 Weeks Range 0.01 - 2.51	Updated Date 04/16/2024
52 Weeks Range 0.01 - 2.51	Updated Date 04/16/2024
Dividends yield (FY) -	Basic EPS (TTM) -

Earnings Date

Report Date -

When -

Estimate -

Actual -

Profitability

Profit Margin -

Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -

Return on Equity (TTM) -

Valuation

Trailing PE -	Forward PE -	Enterprise Value -	Price to Sales(TTM) -
Enterprise Value -	Price to Sales(TTM) -
Enterprise Value to Revenue -	Enterprise Value to EBITDA -	Shares Outstanding -	Shares Floating -
Shares Outstanding -	Shares Floating -
Percent Insiders -	Percent Institutions -

Analyst Ratings

Rating 3.5	Target Price -	Buy 1	Strong Buy -
Buy 1	Strong Buy -
Hold 1	Sell -	Strong Sell -
Strong Sell -

About Gamida Cell Ltd

Exchange NASDAQ	Headquaters Boston, MA, United States
IPO Launch date -	President, CEO & Director Ms. Abigail L. Jenkins M.S.
Sector Healthcare	Industry Biotechnology	Full time employees 145	Website https://www.gamida-cell.com
Full time employees 145	Website https://www.gamida-cell.com

Gamida Cell Ltd. researches, develops, and commercializes cell therapies. The company offers Omisirge (omidubicel-onlv), a cell therapy for use in treatment of patients with hematologic malignancies and severe aplastic anemia. Its product candidate includes GDA-201, an investigational NK cell-based cancer immunotherapy, for the treatment of hematologic and solid tumors, as well as to treat follicular and diffuse large B-cell lymphomas which is in phase 1 of phase1/2 clinical trial. The company was incorporated in 1998 and is based in Boston, Massachusetts.

https://www.upturn.io

Disclosure Privacy Policy Terms of Use Sitemap Contact Us

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.